Initiation of Phase 3 trial of CHS-0214 (Investigational Etanercept Biosimilar) in Japan (RApsody)
18 August 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced the start of the Phase 3 trial of CHS-0214, an investigational etanercept biosimilar1, in rheumatoid arthritis (the RApsody trial) in Japan...